Ablacon, a Colorado-based company in the USA specialising in atrial fibrillation technology, has announced that it has raised $21.5 million in a Series A financing round led by Ajax Health.

Ablacon’s innovative algorithm uses artificial intelligence (AI) to analyse and visualise the flow of action potentials, or Electrographic Flow, within the heart in order to identify sources and drivers of atrial fibrillation, the most common cardiac arrhythmia worldwide. The map of the Electrographic Flow can help to guide physicians in targeted catheter ablation therapy.

The company will use the Series A funding to advance its technology pipeline and finance clinical trials.

“The idea to leverage techniques and algorithms from computer vision to analyze electric signals in the heart is ingenious. Ablacon combines concepts from both the medical world and machine intelligence in a way that I think is very promising,” said Leibniz Prize holder Daniel Cremers, Professor and Chair for Computer Vision and Pattern Recognition at the Technical University of Munich.

Ajax Health accelerates medical innovation by identifying opportunities and then taking an operating role in building innovative medical companies that improve lives and bring speed, simplicity and cost efficiency to health care.

As part of the investment, Ajax Health CEO Duke Rohlen will join Ablacon as Chairman and CEO.

Duke commented: “Since our first meeting with Ablacon, we have been impressed with the caliber of the team and the promise of the technology to improve patient care in AFib. I’m thrilled to join the team to advance this exciting project.”

Over 7,000 healthcare professionals stay informed about the latest assistive technology with AT Today. Do you?
We respect your privacy